Gennex Laboratories Ltd

Mon 7/09/2026,12:23:0 | BSE : GENNEX

₹11.86-0.26 (-2.15%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 11.81

Previous Close

₹ 12.12

Volume

217632

Mkt Cap ( ₹ Cr)

₹ 288.14

High

₹ 12.08

Low

₹ 11.80

52 Week High

₹ 17.25

52 Week Low

₹ 7.05

Book Value Per Share

₹ 9.35

Dividend Yield

₹ 0.00

Face Value

₹₹1.00

What's Your Call?

Collective community sentiment on Gennex Laboratories Ltd

Your Vote -

Buy

70.00%

Hold

10.00%

Sell

20.00%

70.00%

20 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Gennex Laboratories Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Gennex Laboratories - Intimation Of Book Closure For The Purpose Of 41St AGM Of Gennex Laboratories Limited

    4 Sep 2026, 5:41PM Pursuant to Regulation 42 of SEBI (LODR) Regulations, 2015, the Register of Members and Share Transfer Books of the Company will remain closed from Se
  • Gennex Laboratories - Board Meeting Outcome for Meeting Held On September 04, 2026

    4 Sep 2026, 5:25PM 1. Draft Directors'/ Board Report for the Financial Year March 31, 2026;\r\n2. The 41st Annual General Meeting of the Company to be held on Wednesday,
  • Gennex Laboratories - Board Meeting Intimation for For Fixing Date, Time And Venue Of 41St AGM Of The Company

    27 Aug 2026, 5:56PM Gennex Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/09/2026 ,inter alia, to consider
  • Gennex Laboratories - Un-Audited Financial Results For The Quarter Ended June 30, 2026

    14 Aug 2026, 5:10PM In just concluded Meeting of Board of Directors, the Board approved and considered the following items:\r\n1. Unaudited Standalone and Consolidated Fi
  • Gennex Laboratories - Board Meeting Outcome for Un-Audited Financial Results For The Quarter Ended June 30, 2026

    14 Aug 2026, 4:56PM In just concluded Meeting of Board of Directors, the Board Approved and considered the following items:\r\n1. Unaudited (Standalone and Consolidated)
  • Gennex Laboratories - Board Meeting Intimation for Consideration And Approval Of The Unaudited Standalone And Consolidated Fi

    29 Jul 2026, 2:36PM Gennex Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider
  • Gennex Laboratories has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2026

    20 Jul 2026, 3:50PM As of June 2026, 23.63% is owned by Indian Promoters and 76.37% by Public. <p align=justify> Top five Promoters holding highest number of shares of Ge
  • Gennex Laboratories - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    17 Jul 2026, 1:28PM With reference to the captioned subject matter, pursuant to Regulation 74(5) of SEBI (DP) Regulations, 2018, we hereby submit the certificate received
  • Gennex Laboratories - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regul

    10 Jun 2026, 4:41PM The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SE
  • Gennex Laboratories - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regul

    10 Jun 2026, 4:39PM The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SE

Key fundamentals

Evaluate the intrinsic value of Gennex Laboratories Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 240.939 186.0388 171.6065 80.0009 54.1213
Liabilities 240.939 186.0388 171.6065 80.0009 54.1213
Equity 24.2948 22.7447 22.7447 18.0192 12.6503
Gross Profit 13.5314 10.3442 12.4188 4.5829 5.378
Net Profit 16.1281 14.0369 11.7979 4.5589 3.9232
Cash From Operating Activities -40.1828 -9.5199 -33.4279 -14.4505 6.6361
NPM(%) 13.45 14.84 17.66 7 6.4
Revenue 119.8567 94.5778 66.7987 65.0981 61.2137
Expenses 106.3253 84.2336 54.3798 60.5151 55.8357
ROE(%) 7.09 6.17 5.19 2 1.72

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Gennex Laboratories Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 862.45 0.48 21.81 6.92 -26.19 0.58
Lotus Eye Hospital and Institute Ltd 109.65 2.14 1578.57 25.21 0.39 0.00
Bharat Immunological and Biologicals Corporation Ltd 15.34 0.00 0.00 52.33 -39.50 0.00
Astec Lifesciences Ltd 551.75 -0.65 0.00 27.01 -363.14 0.00

Company Info

PRUDENTIAL PHARMACEUTICALS LIMITED was originally incorporated under the name of Pharmasia Drugs and Chemicals Private Limited on 25th June, 1985 in the state of Karnataka. The Company was subsequently shifted to Andhra Pradesh with effect from 29th March, 1990. The Company has been promoted by Pharmasia Limited, a Company registered under the Companies Act, 1956 and having its registered office at 49, BHEL Enclave, Akbar Road, Secunderabad - 500 003. The Company had acquired a sick bulk drug manufacturing unit of SPS Chemicals Private Limited, a sick unit assisted by the Andhra Pradesh State Financial Corporation Limited, located at 133, Bollaram, Medak Dist., in an auction in January, 1993 by paying a lumpsum consideration of Rs.13.25 lacs and undertaking to pay off the term loan overdues amounting to Rs.24 lacs to APSFC which has since been paid off. The Company became a Deemed Public Limited Company with effect from 6th February, 1993 as per the provisions of section 43A(1) of the Companies Act, 1956. The Company was converted to a Public Limited Company by a resolution passed by its members at the Extraordinary General Body Meeting held on 3rd November, 1994. A fresh certificate of incorporation consequent upon the conversion of the Company was issued by the Registrar of Companies, Andhra Pradesh, on 15th February, 1995. The Company's name was subsequently changed to Prudential Pharmaceuticals Limited and a fresh certificate of incorporation consequent upon change of name of the Company was issued by the Registrar of Companies, Andhra Pradesh, on 22nd February, 1995. Mr.Vinod Baid & his associates, acquired the entire holding of Pharmasia Limited amounting to 1,40,018 shares at their face value, (the consideration for which has been paid in cash) in November, 1994 with a view to implement the project to set up facilities for manufacturing bulk drugs. The controlling interest held by the erstwhile promoter group was acquired by Mr.Vinod Baid & Associates by transfer of shares by following the procedure set out in the Companies Act, 1956 and the rules framed there under i.e. by executing transfer deeds in prescribed form in favour of the transferees. At the time of take-over, the Company had certain plant and machinery which has been detailed elsewhere in the prospectus and had also placed orders for certain other plant and machinery. After the takeover, the company under the new management had taken up the implementation of the project in right earnest. The products were identified, additional equipment required (other than those already available and those ordered) were acquired and the manpower required for manning the project were hired. The trial production was completed in September, 1995 and the Commercial Production has already commenced. 2007 - Company name has been changed from Prudential Pharmaceuticals Ltd to Gennex Laboratories Ltd. 2009 -Company has splits its Face value of Shares from Rs 10 to Re 1. 2022 -The company issued rights shares of Rs. 1 in the ratio of 1:2 at a premium of Rs. 5 per share.2023-The Company has received World Health Organization Good Manufacturing Practice (WHO-GMP) Certificate from the Drug Control Administration, Government of Telangana, for a period of three years for the products,  Guaifenesin  USP/BP/EP/IP,  Methocarbamol USP/IP,  Phenazopyridine Hcl   USP,  Allopurinol USP/EP    2025-Company's subsidiary Company, M/s Deccan Remedies Limited, has received Approval from the Drugs Control Administration, Government of Andhra Pradesh granting manufacture of Additional Products.

PRUDENTIAL PHARMACEUTICALS LIMITED was originally incorporated under the name of Pharmasia Drugs and Chemicals Private Limited on 25th June, 1985 in the state of Karnataka. The Company was subsequently shifted to Andhra Pradesh with effect from 29th March, 1990. The Company has been promoted by Pharmasia Limited, a Company registered under the Companies Act, 1956 and having its registered office at 49, BHEL Enclave, Akbar Road, Secunderabad - 500 003. The Company had acquired a sick bulk drug manufacturing unit of SPS Chemicals Private Limited, a sick unit assisted by the Andhra Pradesh State Financial Corporation Limited, located at 133, Bollaram, Medak Dist., in an auction in January, 1993 by paying a lumpsum consideration of Rs.13.25 lacs and undertaking to pay off the term loan overdues amounting to Rs.24 lacs to APSFC which has since been paid off. The Company became a Deemed Public Limited Company with effect from 6th February, 1993 as per the provisions of section 43A(1) of the Companies Act, 1956. The Company was converted to a Public Limited Company by a resolution passed by its members at the Extraordinary General Body Meeting held on 3rd November, 1994. A fresh certificate of incorporation consequent upon the conversion of the Company was issued by the Registrar of Companies, Andhra Pradesh, on 15th February, 1995. The Company's name was subsequently changed to Prudential Pharmaceuticals Limited and a fresh certificate of incorporation consequent upon change of name of the Company was issued by the Registrar of Companies, Andhra Pradesh, on 22nd February, 1995. Mr.Vinod Baid & his associates, acquired the entire holding of Pharmasia Limited amounting to 1,40,018 shares at their face value, (the consideration for which has been paid in cash) in November, 1994 with a view to implement the project to set up facilities for manufacturing bulk drugs. The controlling interest held by the erstwhile promoter group was acquired by Mr.Vinod Baid & Associates by transfer of shares by following the procedure set out in the Companies Act, 1956 and the rules framed there under i.e. by executing transfer deeds in prescribed form in favour of the transferees. At the time of take-over, the Company had certain plant and machinery which has been detailed elsewhere in the prospectus and had also placed orders for certain other plant and machinery. After the takeover, the company under the new management had taken up the implementation of the project in right earnest. The products were identified, additional equipment required (other than those already available and those ordered) were acquired and the manpower required for manning the project were hired. The trial production was completed in September, 1995 and the Commercial Production has already commenced. 2007 - Company name has been changed from Prudential Pharmaceuticals Ltd to Gennex Laboratories Ltd. 2009 -Company has splits its Face value of Shares from Rs 10 to Re 1. 2022 -The company issued rights shares of Rs. 1 in the ratio of 1:2 at a premium of Rs. 5 per share.2023-The Company has received World Health Organization Good Manufacturing Practice (WHO-GMP) Certificate from the Drug Control Administration, Government of Telangana, for a period of three years for the products,  Guaifenesin  USP/BP/EP/IP,  Methocarbamol USP/IP,  Phenazopyridine Hcl   USP,  Allopurinol USP/EP    2025-Company's subsidiary Company, M/s Deccan Remedies Limited, has received Approval from the Drugs Control Administration, Government of Andhra Pradesh granting manufacture of Additional Products.

Parent Organisation

Gennex Laboratories Ltd.

Founded

29/03/1990

Managing Director

Mr.Arihant Baid

NSE Symbol

FAQ